(PharmaNewsWire.Com, March 10, 2017 ) According to the report Europe Cancer Monoclonal Antibodies Market, published by Market Data Forecast, the Europe market is projected to reach USD 11.8 billion by 2020, at a CAGR of 10.9% from 2015 to 2020
Cancer is the leading cause of death currently across the globe. It starts with a single cell genetically transforming normal cell into tumour and is spread gradually to the other cells. The dramatic increases in the number of cancer cases have prompted many pharmaceutical companies to invest in monoclonal antibodies. The practise for curing cancer currently includes usage of drugs and chemotherapy which have adverse side effects. These prompted the usage of Monoclonal antibodies.
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat the disease. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to cancer. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the cancerous cells not affecting the normal ones.
The dramatic increase of the number of cancer patients has led many pharmaceutical players to invest in monoclonal antibodies market. Increasing investment in technological advancements in genetic sequencing, research and development of genomic studies and target gene selection, specificity of monoclonal antibodies to target only the cancer cells with no side effects are the some of the driving forces of the market. Increased prevalence of cancer being the key driver for the monoclonal antibodies market, it is expected to grow lucratively in the next 5 years with the presence of strong products in the pipeline. However, there are few restraints for the growth of the market like high development cost being the major one. And also, long durations required for the research and development of antibodies, stringent regulatory guidelines, longer periods of clinical trials are some of the hurdles faced by the market.
The Cancer Monoclonal Antibodies Market is segmented as following: Based on Application: Liver Breast Brain Blood Hodgkins and Non-Hodgkins lymphoma Colorectal Leukaemia Others Based on Type: Murine Antibodies Chimeric and Humanised Antibodies Fully Humanized Antibodies Based on Conjugate Cancer Therapies: Immunoliposome Radioimmunotherapy ADEPT Immunocytokines Others
The major companies operating in the Europe Cancer Monoclonal Antibodies Market are Amgen, Bristol Myers Squibb, Roche, Immunogen, Novartis, Seattle Genetics, Eli Lilly, Spectrum Pharmaceuticals, Genmab, and glaxosmithkline.
The Cancer Monoclonal Antibodies Market study offers the following deliverables: Europe, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics Study of the effect of exogenous and endogenous factors that affect the Europe market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis Study the micro environment factors that determine the overall profitability of an Industry, using Porters five forces analysis for analysing the level of competition and business strategy development A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
